**Figure S4. Legend**: Waterfall Plots showing maximum reduction in the sum of diameters of target tumors, Gastric (A), NSCLC (B), TNBC (C), HNSCC (D) and Other (E) compared to baseline in patients from phase 1 and phase 2 with at least one post-baseline CT scan (n=167). Yellow bars indicate patients treated with vopratelimab monotherapy; blue bars indicate patients treated with vopratelimab in combination with nivolumab. NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer; HNSCC, head and neck squamous cell carcinoma. Data cut date: 07-22-2020

**Figure S4. Waterfall plots of maximum percent change from baseline (Investigator RECIST 1.1) by tumor type and treatment**

